Skip to content
Loading…
City Therapeutics Inc., an early-stage developer of RNAi-based drugs, raised $200 million in a US initial public offering priced at the mid-point of its marketed range.
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.